About StratifAI
StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Its discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers.
Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, helping refine adjuvant treatment options. Retrospectively validated on thousands of patients from Phase III trials and in real-world clinical settings, Polaris™ Breast is available for research-use only and is undergoing regulatory approval in the EU and US.
Advertisement
News about StratifAI
Here you will find StratifAI GmbH
Last viewed contents
Immunotope, Inc. - Doylestown PA, USA
Spin-off offers purification tool to tackle viral gene therapy manufacturing bottlenecks - Higher speed and increased yield thanks to membrane-based steric exclusion chromatography
One in six college students misuse ADHD stimulant drugs
NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD
Herpes virus to be weaponized to fight cancer - Viral immunotherapy could also prove effective against metastases
New gene transporter to trick the immune system - Junior scientist receives 60.000 euro prize for research on haemophilia A therapy
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases
BioServe - Beltsville, USA
